Human and mouse VEGFA-amplified hepatocellular ......2014/03/29 · Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782 3 Research Foundation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly
sensitive to sorafenib treatment
Elad Horwitz1, Ilan Stein1,2, Mariacarla Andreozzi3, Julia Nemeth4, Avivit Shoham1, Orit
Pappo2, Nora Schweitzer5, Luigi Tornillo3, Naama Kanarek1, Luca Quagliata3, Farid
Zreik2, Rinnat M. Porat2, Rutie Finkelstein1,2, Hendrik Reuter6, Ronald Koschny11, Tom
Ganten11, Carolin Mogler7, Oren Shibolet8, Jochen Hess4,9,10, Kai Breuhahn7, Myriam
Grunewald12, Peter Schirmacher7, Arndt Vogel5, Luigi Terracciano3, Peter Angel4, Yinon
Ben-Neriah1 & Eli Pikarsky1,2
1 - The Lautenberg Center for Immunology, IMRIC, Hebrew University - Hadassah
Medical School, Jerusalem, Israel
2 - Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem,
Israel
3 - Institute of Pathology, University Hospital Basel, Basel, Switzerland
4 - Division of Signal Transduction and Growth Control (A100), German Cancer
Research Center (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, Germany
5 - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
School, Hannover, Germany
6 - Division of Molecular Genetics (B060) German Cancer Research Center (DKFZ),
Heidelberg, Germany
7 - Institute of Pathology, University Hospital Heidelberg, Germany
8 - Liver Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
1. Farazi, P.A., and DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006. 6:674-687.
2. El-Serag, H.B. Hepatocellular carcinoma. N Engl J Med 2011. 365:1118-1127. 3. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., et al. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med 2008. 359:378-390. 4. Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., et al. Efficacy and safety of sorafenib
in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009. 10:25-34.
5. Iavarone, M., Cabibbo, G., Piscaglia, F., Zavaglia, C., Grieco, A., Villa, E., et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011. 54:2055-2063.
6. Jia, N., Liou, I., Halldorson, J., Carithers, R., Perkins, J., Reyes, J., et al. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. Anticancer Res 2013. 33:2797-2800.
7. Balsom, S.M., Li, X., Trolli, E., Rose, J., Bloomston, M., Patel, T., et al. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology 2010. 78:210-212.
8. Brunocilla, P.R., Brunello, F., Carucci, P., Gaia, S., Rolle, E., Cantamessa, A., et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol 2013. 30:345.
9. Dai, X., Schlemmer, H.P., Schmidt, B., Hoh, K., Xu, K., Ganten, T.M., et al. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Radiol 2013. 82:327-334.
10. Llovet, J.M., Pena, C.E., Lathia, C.D., Shan, M., Meinhardt, G., Bruix, J., et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012. 18:2290-2300.
11. Tsukui, Y., Mochizuki, H., Hoshino, Y., Kawakami, S., Kuno, T., Fukasawa, Y., et al. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Hepatogastroenterology 2012. 59:2536-2539.
12. Strebhardt, K., and Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008. 8:473-480.
13. Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., and Llovet, J.M. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010. 30:35-51.
14. Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005. 353:1659-1672.
15. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'Callaghan, C.J., Tu, D., Tebbutt, N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008. 359:1757-1765.
16. Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004. 64:7099-7109.
17. Govindarajan, R., Siegel, E., Makhoul, I., and Williamson, S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol 2013. 36:254-257.
18. Siegel, A.B., Cohen, E.I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J.J., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008. 26:2992-2998.
19. Thomas, M.B., Morris, J.S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009. 27:843-850.
20. Yau, T., Wong, H., Chan, P., Yao, T.J., Pang, R., Cheung, T.T., et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs 2012. 30:2384-2390.
21. Ferrara, N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009. 29:789-791. 22. Lichtenberger, B.M., Tan, P.K., Niederleithner, H., Ferrara, N., Petzelbauer, P., and Sibilia, M.
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140:268-279.
23. Chatterjee, S., Heukamp, L.C., Siobal, M., Schöttle, J., Wieczorek, C., Peifer, M., et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 2013. 123:1732-1740.
24. LeCouter, J., Moritz, D.R., Li, B., Phillips, G.L., Liang, X.H., Gerber, H.P., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003. 299:890-893.
25. Ding, B.S., Nolan, D.J., Butler, J.M., James, D., Babazadeh, A.O., Rosenwaks, Z., et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010. 468:310-315.
26. Hernandez-Gea, V., Toffanin, S., Friedman, S.L., and Llovet, J.M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013. 144:512-527.
27. Mauad, T.H., van Nieuwkerk, C.M., Dingemans, K.P., Smit, J.J., Schinkel, A.H., Notenboom, R.G., et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994. 145:1237-1245.
28. Shukla, R., Upton, K.R., Munoz-Lopez, M., Gerhardt, D.J., Fisher, M.E., Nguyen, T., et al. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell 2013. 153:101-111.
29. Chiang, D.Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008. 68:6779-6788.
30. Chochi, Y., Kawauchi, S., Nakao, M., Furuya, T., Hashimoto, K., Oga, A., et al. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol 2009. 217:677-684.
31. Patil, M.A., Gutgemann, I., Zhang, J., Ho, C., Cheung, S.T., Ginzinger, D., et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 2005. 26:2050-2057.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
32. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010. 463:899-905.
33. Moinzadeh, P., Breuhahn, K., Stutzer, H., and Schirmacher, P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer 2005. 92:935-941.
34. Ouchi, K., Sugawara, T., Ono, H., Fujiya, T., Kamiyama, Y., Kakugawa, Y., et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg 2000. 17:42-48.
35. Qian, B.Z., and Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010. 141:39-51.
36. Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008. 18:349-355.
37. Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Jung, S., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006. 124:175-189.
38. Mahasreshti, P.J., Navarro, J.G., Kataram, M., Wang, M.H., Carey, D., Siegal, G.P., et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001. 7:2057-2066.
39. Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009. 15:21-34.
40. Trusolino, L., Bertotti, A., and Comoglio, P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010. 11:834-848.
41. Whittaker, S., Marais, R., and Zhu, A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010. 29:4989-5005.
42. Wyckoff, J.B., Wang, Y., Lin, E.Y., Li, J.F., Goswami, S., Stanley, E.R., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007. 67:2649-2656.
43. Albertson, D.G. Gene amplification in cancer. Trends Genet 2006. 22:447-455. 44. Weir, B.A., Woo, M.S., Getz, G., Perner, S., Ding, L., Beroukhim, R., et al. Characterizing the
cancer genome in lung adenocarcinoma. Nature 2007. 450:893-898. 45. Tsafrir, D., Bacolod, M., Selvanayagam, Z., Tsafrir, I., Shia, J., Zeng, Z., et al. Relationship of gene
expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006. 66:2129-2137.
46. Vlajnic, T., Andreozzi, M.C., Schneider, S., Tornillo, L., Karamitopoulou, E., Lugli, A., et al. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients. Mod Pathol 2011.
47. Horlings, H.M., Lai, C., Nuyten, D.S., Halfwerk, H., Kristel, P., van Beers, E., et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res 2010. 16:651-663.
48. Lau, C.C., Harris, C.P., Lu, X.Y., Perlaky, L., Gogineni, S., Chintagumpala, M., et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004. 39:11-21.
49. Andreozzi, M., Quagliata, L., Gsponer, J.R., Ruiz, C., Vuaroqueaux, V., Eppenberger-Castori, S., et al. VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities. Angiogenesis 2013.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
50. Yang, J., Yang, D., Sun, Y., Sun, B., Wang, G., Trent, J.C., et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 2011. 117:4925-4938.
51. Schneider, B.P., Gray, R.J., Radovich, M., Shen, F., Vance, G., Li, L., et al. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 2013. 19:1281-1289.
52. Salido, M., Tusquets, I., Corominas, J.M., Suarez, M., Espinet, B., Corzo, C., et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005. 7:R267-273.
53. Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007. 25:118-145.
54. Kamimura, S., and Tsukamoto, H. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. Hepatology 1995. 22:1304-1309.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782
Published OnlineFirst March 31, 2014.Cancer Discovery Elad Horwitz, Ilan Stein, Mariacarla Andreozzi, et al. are highly sensitive to sorafenib treatmentHuman and mouse VEGFA-amplified hepatocellular carcinomas
Updated version
10.1158/2159-8290.CD-13-0782doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerdiscovery.aacrjournals.org/content/early/2014/03/29/2159-8290.CD-13-0782To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/2159-8290.CD-13-0782